Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)

NCT07691606 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT07691606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 22, 2026
Completion date
December 31, 2030
Enrollment
140 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non hodgkin lymphoma